BIOTECH

More in BIOTECH

• EU clears Pfizer's $43 bn takeover of biotech firm Seagen

  Pfizer announced in March its deal with Seagen, which is based in Washington state and leads in the research, development and commercialisation of cancer treatments.

  

• India emerging as a hub for clinical trials, says Parexel

  "In the past, if they wanted to do clinical trials in 28 countries, India used to be 20th on the list. But, now, India started popping up among the top 5-10 countries (to do trials)," said Sanjay Vyas, EVP, safety & logistics and country head. “Over 90 new applications came in the last 18 months and this was to do studies in India by largely global pharma and a couple of local multinationals as well,” Vyas said.

  

• Syneos taken private for $4.46 bln by investment consortium

  The consortium will pay about $43 per share in cash, which represents a premium of about 12 per cent to Syneos' last close. The acquisition is valued at $7.1 billion including debt. North Carolina-based Syneos has been facing challenges in winning new business as many of its clients, which include small and medium-sized biotech companies, have cut spending amid difficulties raising funding in a post-COVID market downturn.

  

• Amid rising viral cases, Bharat Biotech working on H3N2 vaccine

  I am a scientist. Definitely we are working on it (H3N2 virus vaccine). We have started the work and we are expecting the next pandemic will come in flu. Also I have been telling that it is moving from bird flu, pig and poultry and also in humans: Dr Krishna Ella

  

• Danish biotech Gubra aims to raise DKK 500 mln in IPO

  Certain investors, including Danske Asset Management and Danica Pension have committed to subscribe for Gubra's new shares for a total amount of 330 million crowns.

  

• Big private hospitals aren't stocking up on nasal vaccine amid poor demand

  The vaccine was supposed to be available only in private hospitals as the government did not procure it as well. Bharat Biotech did not respond to a request for comment.

  

• Mylab rolls out conventional kits, devices designed for small to medium-sized labs

  Mylab’s new range of medical devices and kits, claims to offer conventional diagnostic solutions to enable a decentralised diagnostic ecosystem, which will allow small labs and clinics to offer quality diagnostics faster than before, by offering devices which have smaller reagent packs, with smaller sample volume requirements, and better sensitivity and linearity.

  

• Make nasal vaccines against COVID-19 free, Tamil Nadu urges Centre

  The centre launched Indian-made nasal vaccine against COVID-19, iNCOVACC. The vaccine, manufactured by Bharat Biotech, in December, will be available at private vaccination centres.

  

• Union Health Minister to launch world's first Made-in-India COVID-19 nasal vaccine tomorrow

  ​Earlier this month, Bharat Biotech received approval from the Central Drugs Standard Control Organisation (CDSCO) for the use of heterologous booster doses of iNCOVACC. The vaccine is still not available on CoWin.

  

• Covaxin was not a fluke, says Bharat Biotech MD

  As there was a high pressure to manufacture an indigenous vaccine within a time limit, we produced the first covaxin in 30 days in an extremely challenging environment : Suchitra Ella

  

• Administering 220 crore doses of Covid vaccine in India highpoint of 2022

  Expanding the scope of its Covid vaccination drive, India began inoculating adolescents in the age group of 15-18 years from January 3 and administering precaution doses to healthcare and frontline workers and those aged 60 and above with comorbidities from January 10.